Summary

Myogem has received a patent granting rights to Myogem CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2. This groundbreaking discovery involves compounds that serve as active agents in models of Distrofia Miotónica. The team also secured a 2017 patent and a licensing deal with Myogem in the United States. A significant milestone was awarded in 2019, where Myogem was honored with the Excellence Seal. The organization participates actively in the European Eurordis Summer School Spanish Edition. Furthermore, my research presented results in IDMC-12 regarding PreClínicos studies of MyoDM, contributing to a 2017 patent granted in the US. The success of this clinical trial concluded successfully with the recruitment of patients in Distrofia Miotónica Type 1. In addition to clinical progress, Myogem has launched a new clinical development study aimed at myotonic dystrophy type 1.

Title

Home - Myogem

Description

This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most

Keywords

para, health, company, treatment, dystrophy, type, fases, general

NS Lookup

A 213.158.93.24

Dates

Created 2026-03-09

Updated 2026-04-05

Summarized 2026-04-05